Compare · NVO vs SXTP
NVO vs SXTP
Side-by-side comparison of Novo Nordisk A/S (NVO) and 60 Degrees Pharmaceuticals Inc. (SXTP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SXTP operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 48633.7x SXTP ($3.9M).
- NVO has been more active in the news (11 items in the past 4 weeks vs 9 for SXTP).
- NVO has more recent analyst coverage (25 ratings vs 0 for SXTP).
- Company
- Novo Nordisk A/S
- 60 Degrees Pharmaceuticals Inc.
- Price
- $42.01-2.10%
- $1.46-2.67%
- Market cap
- $187.53B
- $3.9M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2023
- News (4w)
- 11
- 9
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
Latest SXTP
- 60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
- 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis
- SEC Form 3 filed by new insider Francois Eric
- 60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.
- 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results
- SEC Form 10-Q filed by 60 Degrees Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by 60 Degrees Pharmaceuticals Inc.
- 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website